Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates

Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates Written by MarketBeat August 17, 2026 Add As Preferred Source Share Share Share This Article Link copied to clipboard. Close Image from MarketBeat Media, LLC. Key Points AI platform and partnerships: Recursion has accumulated more than 50 petabytes of multimodal biological data to support AI-driven drug discovery. Its Roche collaboration has produced a novel neuroscience target and could support up to 40 design programs, while five Sanofi programs have reached initial discovery milestones. Pipeline progress: Lead FAP candidate REC-4881 delivered a reported reduction of more than 40% in polyp burden after three months, with longer-term data and FDA pivotal-trial discussions expected. The company also expects updates on oncology drug REC-1245 and a PI3K alpha inhibitor later this year. Financial outlook: Recursion has cut expenses by about 40% from its pre-merger level and ended the quarter with $556 million in cash, which it expects to fund operations into at least early 2028 without additional financing. Five stocks we like better than Recursion Pharmaceuticals . 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Taylor said during a BofA Global Research virtual conference. Taylor described AI not as a “magic wand,” but as a more capable analytical system that can help researchers produce and interpret data across multiple biological parameters. Recursion’s central objective, he said, is to improve the probability of success in drug development by identifying biological and chemical opportunities that conventional approaches may miss. Get RXRX alerts: Sign Up These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio “The foundation of the company is actually around changing the probability of success and really trying to unlock new parts of biology and chemistry rather than efficiency,” Taylor said. He added that the company has also reported reductions in the time and cost required to advance differentiated drug-discovery programs. Data strategy and AI platform Taylor said Recursion has spent more than a decade generating data designed for machine-learning applications, rather than relying solely on fragmented, project-specific data typically created across the biopharma industry. The company has accumulated more than 50 petabytes of data, he said, including phenotypic cellular imaging, transcriptomics, proteomics and real-world patient data. Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite? Recursion uses these data types together to improve the biological signals generated by its models. Taylor cited a recently published Nature Biotechnology paper in which Recursion said its models outperformed models trained on datasets up to 100 times larger because its data were more thoroughly annotated and incorporated multiple modalities. The company’s platform is intended to help expand research beyond targets already widely studied by drug developers. Taylor said approved drugs address about 3.5% of the genome, while including drugs currently in development raises coverage to roughly 13%. “The reality is we keep digging in the same holes,” Taylor said. “What we want to do is create new data, look at it in new ways, so that we can actually break outside of those holes.” Roche and Sanofi collaborations Recursion recently selected its first novel neuroscience target for further drug development under its collaboration with Roche. Taylor said Roche initially provided $150 million for Recursion to build biological maps in neuronal and microglial cells. Roche later opted into both maps through two $30 million payments, allowing it to qu...